Market Overview

Generation Bio Appoints Charles Rowland to its Board of Directors


, a company developing the first genetic medicines that can be
titrated to effect and re-dosed for a lifetime of benefit, announced the
appointment of Charles Rowland to its Board of Directors.

"I'm so pleased to welcome Charlie to our Board," said Geoff McDonough,
M.D., president and chief executive officer of Generation Bio. "Charlie
brings more than 30 years of industry perspective to our work here, with
especially strong financial, capital markets, and strategy experience in
a variety of fields, including a strong track record in rare disease."

Rowland is currently an independent board member and strategic advisor
for multiple biotechnology companies including Blueprint Medicines and
Orchard Therapeutics, and previously served as chief executive of
Aurinia Pharmaceuticals. Prior to that he was the vice president and
chief financial officer of ViroPharma, Inc., where he led and designed
the company's mid- and long-term business strategy until it was acquired
by Shire PLC. From 2006-2008, he served as executive vice president and
chief financial officer, as well as interim co-chief executive officer
for Endo Pharmaceuticals, where he optimized capital structure to
enhance future business initiatives. Additionally, he held leadership
positions at BioVail Pharmaceuticals, Breakaway Technologies, Pharmacia,
Novartis and Bristol-Myers Squibb.

"Charlie is a seasoned industry executive with deep background in
capital allocation and strategy," said Jason Rhodes, a partner at Atlas
Venture and a founder and chairman of Generation Bio's Board of
Directors. "We look forward to drawing on both his financial and
operational expertise as we move through the next phases of growth."

"Generation Bio is working to usher in a transformative era of genetic
medicines with its unique approach to delivering gene therapy to address
a wide range of rare diseases," said Rowland. "I am delighted to join an
exceptional company that is focused on transforming the lives of
patients suffering from genetic diseases with a technology that is truly

About Generation Bio

Generation Bio is a biotechnology company developing a breakthrough
class of genetic medicines to enable a new generation of people
unaffected by inherited disease. The company's therapies are based on
its proprietary GeneWaveTM technology, which delivers
durable, high levels of gene expression and can be re-dosed to titrate
to effect and to sustain impact over a lifetime. Generation Bio was
founded and launched by Atlas Venture and is headquartered in Cambridge,
Mass. For more information, please visit or
follow @lifetimegenetx.

View Comments and Join the Discussion!